article
A careful calibration: balancing small molecule needs and biologic innovation
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
List view / Grid view
Biotech
news
AI/ML investment strong as UK biotech weathers economic strain
With Q3 2025 venture capital figures representing “a fragile moment” for the UK biotech sector, BIA says sustained government action is needed to secure its global competitive edge.
news
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn
Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.
news
Bayer breaks ground on German cell and gene therapy centre
Once completed, the Berlin site will also be the new home for one of the company’s Bayer Co. Lab start-up incubators.
news
Servier acquires treatment for autism genetic cause Fragile X syndrome
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.
news
Demand for AI-integration propelling mass spectrometry growth
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
news
FDA waives trial requirement for Stelera biosimilar, easing the copycat’s path
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
news
EU Biotech Act public consultation opens for input
The European Commission hopes its planned legislation will enable biotechnology companies to bring products from laboratory to market more quickly.
